Patents by Inventor Johannes Foekens

Johannes Foekens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT
    Publication number: 20120165287
    Abstract: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
    Type: Application
    Filed: March 2, 2012
    Publication date: June 28, 2012
    Applicant: Wilex AG
    Inventors: Wolfgang SCHMALIX, Anneliese Schneider, Buddy Setyono-Han, Johannes Foekens
  • Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
    Publication number: 20080226624
    Abstract: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 18, 2008
    Inventors: Wolfgang Schmalix, Anneliese Schneider, Buddy Setyono-Han, Johannes Foekens
  • Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors
    Publication number: 20080019910
    Abstract: Disclosed is a method for improving cancer therapy that relies on induction of apoptosis in malignant cells. It has been found that docking of protease inhibitors PAI-1 and TIMP-1 renders malignant cells expressing these inhibitors more sensitive to apoptosis, whereas non-malignant cells do not change their sensitivity to apoptosis induction. It is therefore possible to increase the effect of various anti-cancer treatments in a rational manner and to predict whether or not an apoptosis-inducing cancer treatment will be effective in a patient or not. The invention also provides for methods of identifying agents that inhibit the apoptosis sensitivity modulating effects of protease inhibitors and to methods of identifying anti-cancer compounds that are not dependent on an apoptosis inducing mechanism which can be modulated by protease inhibitors.
    Type: Application
    Filed: March 30, 2005
    Publication date: January 24, 2008
    Inventors: Maria Romer, Ulrik Lademann, Kenneth Hofland, Peter Jensen, Marion Van Gelder, Johannes Foekens, Anne-Sofie Rasmussen, Nils Brunner, Pernille Usher